Market Newsdesk

PHOENIX, April 03, 2026 (GLOBE NEWSWIRE) — DBM Global Inc. (“DBMG”), a family of companies providing fully integrated steel construction services, and an operating subsidiary of INNOVATE Corp. (NYSE: VATE), announced today that it will pay a cash dividend of approximately $3 million, or $0.78 per share, on April 28, 2026 to DBMG’s stockholders of record at the close of business on April 13, 2026.

About DBM Global Inc.

DBMG is focused on delivering world class, sustainable value to its clients through a highly collaborative portfolio of companies which provide better designs, more efficient construction, and superior asset management solutions. The Company offers integrated steel construction services from a single source and professional services which include design-assist, design-build, engineering, detailing, BIM co-ordination, steel modeling/detailing, fabrication, rebar detailing, advanced field erection, project management, and state-of-the-art steel management systems.  Major market segments include commercial, healthcare, convention centers, stadiums, gaming and hospitality, mixed use and retail, industrial, public works, bridges, transportation, and international projects. The Company, which is headquartered in Phoenix, Arizona, has operations in the United States, Australia, Canada, India, New Zealand, the Philippines and the United Kingdom.

For additional information on DBMG’s majority shareholder, INNOVATE Corp. (NYSE: VATE), please visit http://www.innovatecorp.com or contact:  

Investor Contact:

Solebury Strategic Communications
Anthony Rozmus
(212) 235-2691
Email: [email protected]

Contact:	DBM Global Inc.
	Michael R. Hill, CFO and VP
	(602) 257-7838
	Email: [email protected]

Office of the CEO Established to Oversee Business Operations 

Board Forms Transition Committee and Commences CEO Search

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced leadership and governance changes, including the establishment of an Office of the CEO and the formation of a new Transition Committee of the Board of Directors (“the Board”). These actions follow Tara Comonte’s departure from the Company, effective March 31, 2026. 

The Company’s Board of Directors has initiated a comprehensive search for a permanent successor with the support of a leading executive search firm. During the transition period, the Office of the CEO will oversee business operations and execution of the Company’s strategy. The Office of the CEO comprises Felicia DellaFortuna, Chief Financial Officer, and Jon Volkmann, Chief Operations Officer. In addition, the Board is in conversations to appoint an interim CEO who will lead the Office of the CEO. In parallel, the Board has formed a Transition Committee to oversee the Office of the CEO, conduct the CEO search process and advance ongoing board refreshment and governance matters. The Transition Committee includes Gene Davis, Carney Hawks, Mike Mason and Nikolaj Sjoqvist. 

The Board commented, “Over the past year, the Company has strengthened its financial foundation, advanced its strategic transformation and positioned itself for long-term growth. We have a trusted brand, a highly engaged, loyal member base and a strong leadership team with broad expertise across clinical care, technology, marketing and operations. While we remain confident in our strategy and long-term prospects, there is more work to be done, and the Board looks forward to collaborating with the Office of the CEO and management team to position Weight Watchers as the premier global destination for weight health. We will work diligently to identify a leader with the experience and capabilities necessary to guide the Company in its next phase.”

Separately, the Company announced that Debra Cotter has been appointed chief legal officer and secretary following the planned departure of Jacqueline Cooke as chief legal and administrative officer and secretary, effective April 10, 2026.

The Board commented, “We congratulate Debra on this well-deserved promotion and appreciate her dedication during this important time for Weight Watchers.”

Board Update 

The Company also announced the resignations of Julie Bornstein and Fallon O’Connor as directors on the Board. Ms. Bornstein and Ms. O’Connor’s departures were not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. 

As part of its ongoing focus on strong governance, the Board Transition Committee will oversee the evaluation of future board composition in alignment with the Company’s evolving needs. 

Additional Information Regarding the Executive Transition

The Company noted that Ms. Comonte’s departure was effective on the day that her employment agreement with the Company was scheduled to expire.

First Quarter 2026 Estimates and Full Year 2026 Financial Guidance

In connection with today’s announcement, Weight Watchers reaffirmed its first quarter 2026 end of period subscriber estimates and full year 2026 financial guidance as previously provided on March 16, 2026, in conjunction with the Company’s fourth quarter and full year 2025 results.

About Weight Watchers

Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “forecasts,” “guidance,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 as well as any subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings the Company makes with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this Form 8-K. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For investor inquiries, please contact:

John Mills or Anna Kate Heller
[email protected] 

For media inquiries, please contact:

Lizzy Levitan
[email protected]

WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 685,718 shares of the Company’s common stock to five newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of March 31, 2026 (the “Effective Date”). The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $1.68 per share, which is equal to the closing price of the Company’s common stock on the Effective Date. The options have a ten year term, with 25% vesting on the first anniversary of the Effective Date and the remaining 75% vesting in 36 equal monthly installments thereafter. The options are subject to the terms and conditions of the Inducement Plan approved by the Company’s Board of Directors in March 2026 and the terms and conditions of award agreements covering the grants.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients.

Contacts:

Investor Relations:

Michael Moyer
LifeSci Advisors
[email protected]

HOUSTON, April 03, 2026 (GLOBE NEWSWIRE) — Impact BioMedical Inc. (NYSE American: IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from Grassi & Co., CPAs, P.C. that contains a “going concern” qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company’s financial statements for the year ended December 31, 2025.

Again, this announcement does not represent any change or amendment to the Company’s financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2025.

Separately, Impact Biomedical continues with strategic plans to merge with Dr. Ashley’s Ltd. (here), projected to be completed by July 1, 2026.

About Impact Biomedical Inc.

Impact Biomedical Inc. (IBIO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.

Safe Harbor Statement

This press release contains forward-looking statements. These statements involve risks and uncertainties, including the company’s ability to close its pending merger and secure additional financing to address the going concern doubt expressed by its auditors. Actual results may differ materially.

Investor Relations:

[email protected]

www.impactbiomedinc.com

• Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technology
• Results from ongoing Phase 1/2 study in patients with FTD-GRN expected by the end of 2026

SOUTH SAN FRANCISCO, Calif., April 03, 2026 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it has received notification from Takeda of its decision to terminate the collaboration agreement between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN). The decision was driven by strategic considerations and is not related to efficacy or safety data. DNL593 is an investigational progranulin replacement therapy utilizing Denali’s Protein TransportVehicle™ (PTV) to deliver progranulin across the blood-brain barrier to the brain for the treatment of frontotemporal dementia-granulin (FTD-GRN). Denali has led development activities and will regain full control of DNL593 and its intellectual property portfolio.

“While we have greatly valued our partnership, we are pleased to regain full ownership of DNL593. We remain confident in the scientific rationale and the data generated to date, and we look forward to advancing DNL593 independently. We plan to report results from the ongoing Phase 1/2 trial by the end of 2026,” said Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics. “Our TransportVehicle platform is the first FDA-approved blood-brain barrier-crossing technology, enabling a robust portfolio with broad potential across neurodegenerative diseases like frontotemporal dementia, where there are no currently approved treatment options to slow the progression of this devasting disease.”

As previously disclosed, data from the ongoing Phase 1/2 study of DNL593, including biomarker results, are expected by the end of 2026. Enrollment in this study is completed with a total of 40 participants with FTD-GRN. Interim results from Part A of the Phase 1/2 study in healthy volunteers demonstrated dose-dependent increases in cerebrospinal fluid progranulin levels, consistent with robust brain delivery of DNL593. DNL593 was generally well tolerated, and there have been no significant safety signals to date.

About Frontotemporal Dementia (FTD)

FTD is the most common form of dementia in people under 60 years of age. While the progression of symptoms varies by individual, FTD brings an inevitable decline in function together with changes in personality and social behaviors, and sometimes language and/or motor dysfunction. Mutations in the granulin (GRN) gene, which encodes the progranulin (PGRN) protein, generally result in reduced levels of PGRN and are amongst the most common genetic causes of FTD. There are currently no approved medications to stop or slow the progression of FTD or FTD-GRN.

About the Denali TransportVehicle
^™
Platform

The blood-brain barrier (BBB) is essential in maintaining the brain’s microenvironment and protecting it from harmful substances and pathogens circulating in the bloodstream. Historically, the BBB has posed significant challenges to drug development for central nervous system diseases by preventing most drugs from reaching the brain in therapeutically relevant concentrations. Denali’s TransportVehicle^™ (TV) platform is a proprietary technology designed to effectively deliver large therapeutic molecules such as antibodies, enzymes and oligonucleotides throughout the whole body, including the brain, by crossing the BBB after intravenous administration. The TV platform is based on engineered Fc domains that bind to specific natural transport receptors, such as transferrin receptor and CD98 heavy chain amino acid transporter, which are expressed at the BBB and deliver the TV and its therapeutic cargo to the brain through receptor-mediated transcytosis. In animal models, antibodies and enzymes engineered with the TV platform demonstrate more than 10- to 30-fold greater brain exposure than similar antibodies and enzymes without this technology. Oligonucleotides engineered with the TV platform demonstrate more than a 1,000-fold greater brain exposure in primates than systemically delivered oligonucleotides without this technology. Improved exposure and broad distribution in the brain may increase therapeutic efficacy by enabling widespread achievement of therapeutically relevant concentrations of product candidates. The TV platform has been clinically validated and five TV-enabled programs are currently in clinical development.

About Denali Therapeutics

Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform. With a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, plans, timelines and expectations related to Denali’s TransportVehicle™ platform, including its potential application across current and future product candidates and its ability to deliver therapeutics to the brain; plans, timelines and expectations related to DNL593, including the timing and availability of data readouts from the ongoing Phase 1/2 study, the significance of interim data from the Phase 1/2 study including with respect to tolerability and safety, and the potential therapeutic benefit of DNL593; and statements by Denali’s Chief Executive Officer. Actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of risks and uncertainties. These include, but are not limited to, uncertainties related to the FDA’s policies and accelerated approval program; risks arising from adverse economic conditions and their impact on Denali’s business and operations; the possibility of events or changes that could lead to the termination of Denali’s collaboration agreements; challenges associated with Denali’s transition to a commercial company; the ability of Denali and its collaborators to complete the development and, if approved, the commercialization of product candidates; difficulties in patient enrollment for ongoing and future clinical trials; whether the current ongoing trials have been powered sufficiently to demonstrate approvability to regulatory agencies; reliance on third-party manufacturers and suppliers for clinical trial materials; dependence on the successful development of Denali’s blood-brain barrier platform technology and related programs; potential delays or failures in meeting expected clinical trial timelines; the risk that promising preclinical profiles may not be replicated in clinical settings; discrepancies between preclinical, early-stage or preliminary clinical results and outcomes from later-stage trials; the occurrence of significant adverse events or other undesirable side effects; the uncertainty surrounding regulatory approvals required for commercialization in the U.S., Europe or other international jurisdictions; Denali’s ability to advance a pipeline of product candidates or develop commercially successful products; developments relating to Denali’s competitors and its industry, including competing product candidates and therapies; Denali’s ability to obtain, maintain or protect intellectual property rights related to its product candidates; the implementation and success of Denali’s strategic plans for its business, product candidates and blood-brain barrier platform technology; Denali’s ability to obtain additional capital to finance its operations, as needed; Denali’s ability to accurately forecast future financial results in the current environment; and other risks and uncertainties, including those described in Denali’s most recent Annual and Quarterly Reports on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2026, and Denali’s future reports to be filed with the SEC. Except for AVLAYAH™ (tividenofusp alfa-eknm), Denali’s product candidates are investigational, and their safety and efficacy profiles have not yet been established. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali’s expectations, except as required by law.

Investor Contact:
Tyler Nielsen
[email protected]

Media Contact:
Erin Patton
[email protected]

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP informs investors that a securities fraud class action lawsuit has been filed against Aldeyra Therapeutics, Inc., (“Aldeyra” or the “Company”) (NASDAQ: ALDX) on behalf of investors that bought securities between November 3, 2023 and March 16, 2026, inclusive (the “Class Period”).

Investors have until May 29, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION

On March 17, 2026, the Company filed with the United States Securities and Exchange Commission (“SEC”) a current report on Form 8-K, announcing receipt of a 2026 Complete Response Letter (“CRL”) stating that there is “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling” and that “the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.”

The CRL also stated that the “inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings” and that “the totality of evidence from the completed clinical trials does not support the effectiveness of the product.”

On this news, the price of Aldeyra stock went down by $2.99, or approximately 70.7%, to close at $1.24 per share on March 17, 2026.

Why

Wolf Haldenstein Adler Freeman & Herz LLP?:

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

There is no cost or obligation to speak with an attorney.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774
• Email: 
  [email protected]
• Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

BRONX, N.Y., April 03, 2026 (GLOBE NEWSWIRE) — Ponce Bank, National Association, the banking subsidiary of Ponce Financial Group, Inc., has been recognized by S&P Global Market Intelligence as one of the Top 50 Best-Performing U.S. Community Banks of 2025 in the $3 billion to $10 billion asset category, ranking #40 nationally. This recognition underscores the Bank’s strong financial performance while reaffirming its longstanding commitment to community impact and inclusive growth.

S&P Global Market Intelligence’s annual rankings evaluate financial institutions based on key performance indicators including returns, growth, funding, and balance sheet strength, with a particular emphasis on risk profile and long-term stability. Ponce Bank’s placement reflects a balanced approach to performance—delivering solid financial results while continuing to invest in the communities it serves.

“At Ponce Bank, we believe that doing well and doing good go hand in hand,” said Carlos Naudon, President and Chief Executive Officer of Ponce Bank. “We are honored to be recognized among the top-performing community banks in the country. This recognition reflects the strength of our strategy, the dedication of our team, and our continued commitment to serving communities that have historically been overlooked by traditional financial institutions.”

Founded on a mission of expanding access to responsible banking, Ponce Bank continues to focus on relationship-driven service, small business support, and financial inclusion across the New York metropolitan area. As a Minority Depository Institution (MDI) and Community Development Financial Institution (CDFI), the Bank’s performance reflects a model that connects individual financial opportunity with broader community prosperity.

The rankings, launched in 2011, are designed to identify institutions that demonstrate resilience, strategic discipline, and sustainable performance across economic cycles.

Ponce Bank will be formally recognized at the 2026 Community Bankers Conference, hosted by S&P Global Market Intelligence, taking place May 5–7, 2026, in Fort Worth, Texas.

About Ponce Bank N.A.

Ponce Bank, N.A. was founded in the Bronx in 1960 by Puerto Ricans who chose to invest in their community at a time when most financial institutions were leaving. Today, the Bank operates 13 branches across the New York Metro area, with $3.2 billion in assets and over $500 million in capital. Headquartered in the Bronx, Ponce Bank, N.A. is one of the nation’s largest Latino-led Minority Depository Institutions (MDIs) and Community Development Financial Institutions (CDFIs). The Bank directs nearly 75% of its loans to low- and moderate-income neighborhoods and has been ranked #1 in Housing Focus among the 20 largest CDFI banks in terms of Assets, Deposits, and Lending. The Bank’s parent company, Ponce Financial Group, Inc., trades on the NASDAQ under the symbol PDLB.

Contact:

Jane Trachet
+1 (718) 734-7730
[email protected]

PASCAGOULA, Miss., April 03, 2026 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding division recently welcomed former U.S. Sen. Sam Nunn, his wife, Colleen Nunn, and their daughter and ship sponsor Michelle Nunn, for a visit to the shipyard. The visit included a construction update and tour of the future USS Sam Nunn (DDG 133), a Flight III Arleigh Burke-class destroyer named in honor of the senator, and marked their return to Ingalls following the ship’s keel authentication ceremony.

“It was an honor to welcome Sen. Nunn and Michelle Nunn to Ingalls to see first-hand the progress taking place on DDG 133 and to highlight the ship’s advancing construction path toward launch,” Ingalls Shipbuilding President Brian Blanchette said. “Our shipbuilders take tremendous pride in building a ship that will carry Sen. Nunn’s name and his legacy of enduring commitment to national defense.”

During the 24 years of service in the U.S. Senate, Nunn became one of the nation’s most influential voices on defense policy. He spearheaded major initiatives including Department of Defense Reorganization Act and the Nunn‑Lugar Cooperative Threat Reduction Program, which led to the deactivation of more than 7,600 nuclear warheads from former Soviet Union republics. The future USS Sam Nunn honors this legacy of strengthening America’s defense and advancing global security.

Photos accompanying this release are available at: http://hii.com/news/former-sen-sam-nunn-visits-ingalls-shipbuilding-for-update-on-his-namesake-destroyer/.

Nunn expressed appreciation for the shipbuilders working to bring DDG 133 to life. “It is exciting and deeply humbling to see this powerful destroyer taking shape and to witness the exceptional craftsmanship of the Ingalls team,” Nunn said. “I am grateful for the vital role Ingalls plays in ensuring our nation’s strength and readiness.”

Future USS Sam Nunn (DDG 133) is the fifth Flight III Arleigh Burke-class destroyer to be built at Ingalls. Flight III destroyers incorporate substantial design and system upgrades including the AN/SPY 6(V)1 Air and Missile Defense Radar and the Aegis Baseline 10 Combat System that significantly enhance the U.S. Navy’s integrated air and missile defense capabilities and ensure readiness against evolving threats well into the 21st century.

To date, Ingalls Shipbuilding has delivered 36 Arleigh Burke-class destroyers to the U.S. Navy, including the first Flight III, USS Jack H. Lucas (DDG 125) and Ted Stevens (DDG 128). The four Flight III destroyers currently under construction include: Jeremiah Denton (DDG 129), George M. Neal (DDG 131), Sam Nunn (DDG 133), and Thad Cochran (DDG 135). Additionally, Ingalls is in early pre-planning and material procurement phases for John F. Lehman (DDG 137), Telesforo Trinidad (DDG 139), Ernest E. Evans (DDG 141), Charles French (DDG 142), Richard J. Danzig (DDG 143), Intrepid (DDG 145) and Robert Kerrey (DDG 146).

About HII

HII is America’s largest shipbuilder, delivering the world’s most powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers. HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world.

With a more than 140-year history of advancing U.S. national security, HII builds and integrates defense capabilities extending from the core fleet to C6ISR, AI/ML, EW and synthetic training. Headquartered in Virginia, HII’s workforce is 44,000 strong. For more information, visit:

• HII on the web: https://www.HII.com/
• HII on Facebook: https://www.facebook.com/TeamHII
• HII on X: https://www.twitter.com/WeAreHII
• HII on Instagram: https://www.instagram.com/WeAreHII
• HII on LinkedIn: https://www.linkedin.com/company/wearehii

Contact:
Kimberly Aguillard
[email protected]
(228) 355-5663

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6c4fdca5-f68d-4661-8557-f76fb619755a

HAMILTON, N.J., April 03, 2026 (GLOBE NEWSWIRE) — First Bank (Nasdaq Global Market: FRBA) invites participation in a conference call to discuss the Company’s financial and operating performance during its first quarter ending on March 31, 2026.

Event:	Earnings Conference Call – First Quarter 2026
When:	Tuesday, April 28, 2026 at 9:00 a.m. Eastern Time

The direct dial number for the call is 1-800-715-9871, toll free, using the access code 3623576. For those unable to participate in the conference call, a replay will be available on the Company’s website, www.myfirstbank.com.

The conference call will also be available (listen-only) via the Internet by accessing FRBA conference call. The conference call information is also available by accessing the Company’s web address: www.myfirstbank.com – Investor Relations.
                                
Patrick L. Ryan, President and Chief Executive Officer, Andrew L. Hibshman, Chief Financial Officer, Peter J. Cahill, Chief Lending Officer, and Darleen Gillespie, Chief Retail Banking Officer will provide an overview of first quarter 2026 results. The management presentation typically lasts approximately fifteen to thirty minutes, followed by investor questions and discussion. The Company’s first quarter results will be released after the market closes on Monday, April 27, 2026 and will also be available in the “Investor Relations” section of the Company’s website.

About First Bank

First Bank is a New Jersey state-chartered bank with a branch network that traverses the New York to Philadelphia corridor and includes a single location in Palm Beach County, Florida. With $3.96 billion in assets as of December 31, 2025, First Bank offers a full range of deposit and loan products to individuals and businesses in its markets. First Bank’s common stock is listed on the Nasdaq Global Market exchange under the symbol “FRBA”.

Contact

Andrew L. Hibshman, Executive Vice President and CFO
(609) 643-0058, [email protected]

HERNDON, Va., April 03, 2026 (GLOBE NEWSWIRE) — Navient (Nasdaq: NAVI) will host an audio webcast to review its first quarter 2026 results on Wednesday, April 29, 2026, at 8:00 a.m. Eastern Time.

The webcast will be available on Navient.com/investors; a replay of the webcast will be available on the site.

The results and presentations slides will be available the same day by 7:00 a.m. on Navient.com/investors.

In addition to being available on the company’s investor website, the results will be filed with the SEC on a Form 8-K available at SEC.gov.

About Navient

Navient (Nasdaq: NAVI) creates long-term value for customers and investors with responsible lending, flexible refinancing, trusted servicing oversight, and decades of education finance and portfolio management expertise. Through our Earnest business, we help customers confidently achieve financial success through digital financial services. Our employees thrive in a culture of belonging, where they are supported and proud to deliver meaningful outcomes. Learn more on Navient.com.

Contact:

Media: Cate Fitzgerald, 703-831-6347,

[email protected]


Investors: Jen Earyes, 571-592-8582, [email protected]